Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
2.
PLoS One ; 13(11): e0206272, 2018.
Article in English | MEDLINE | ID: mdl-30427865

ABSTRACT

Gravitational stress occurs during space flights or certain physical activities including extreme sports, where the change in experienced gravitational acceleration can reach large magnitudes. These changes include reduction and increase in the physical forces experienced by the body and may potentially induce pathogenic alterations of physiological processes. The immune system is known to regulate most functions in the human organism and previous studies suggest an impairment of the immune function under gravitational stress. However, systematic studies aiming to investigate the effect of gravitational stress on cellular immune response in humans are lacking. Since parabolic flights are considered as feasible model to investigate a short-term impact of gravitational changes, we evaluated the influence of gravitational stress on the immune system by analyzing leukocyte numbers before and after parabolic flight maneuvers in human blood. To correct for circadian effects, samples were taken at the corresponding time points on ground the day before the flight. The parabolic flight maneuvers led to changes in numbers of different leukocyte subsets. Naïve and memory T and B cell subsets decreased under gravitational stress and lower numbers of basophils and eosinophils were observed. Only circulating neutrophils increased during the parabolic flight. The observed changes could not be attributed to stress-induced cortisol effects, since cortisol levels were not affected. Our data demonstrate that the gravitational stress by parabolic flights can affect all parts of the human immune system. Consequently, it is possible that gravitational stress can have clinically relevant impacts on the control of immune responses.


Subject(s)
Aerospace Medicine/trends , Leukocytes/immunology , Space Flight , Weightlessness/adverse effects , Adult , B-Lymphocytes/immunology , B-Lymphocytes/pathology , Female , Granulocytes/pathology , Humans , Hypergravity/adverse effects , Leukocyte Count , Male , T-Lymphocytes/immunology , T-Lymphocytes/pathology
3.
Chest ; 154(3): 617-627, 2018 09.
Article in English | MEDLINE | ID: mdl-29705219

ABSTRACT

BACKGROUND: In this study, we primarily sought to assess the ability of flow cytometry to predict early clinical deterioration and overall survival in patients with sepsis admitted in the ED and ICU. METHODS: Patients admitted for community-acquired acute sepsis from 11 hospital centers were eligible. Early (day 7) and late (day 28) deaths were notified. Levels of CD64pos granulocytes, CD16pos monocytes, CD16dim immature granulocytes (IGs), and T and B lymphocytes were assessed by flow cytometry using an identical, cross-validated, robust, and simple consensus standardized protocol in each center. RESULTS: Among 1,062 patients screened, 781 patients with confirmed sepsis were studied (age, 67 ± 48 years; Simplified Acute Physiology Score II, 36 ± 17; Sequential Organ Failure Assessment, 5 ± 4). Patients were divided into three groups (sepsis, severe sepsis, and septic shock) on day 0 and on day 2. On day 0, patients with sepsis exhibited increased levels of CD64pos granulocytes, CD16pos monocytes, and IGs with T-cell lymphopenia. Clinical severity was associated with higher percentages of IGs and deeper T-cell lymphopenia. IG percentages tended to be higher in patients whose clinical status worsened on day 2 (35.1 ± 35.6 vs 43.5 ± 35.2, P = .07). Increased IG percentages were also related to occurrence of new organ failures on day 2. Increased IG percentages, especially when associated with T-cell lymphopenia, were independently associated with early (P < .01) and late (P < .01) death. CONCLUSIONS: Increased circulating IGs at the acute phase of sepsis are linked to clinical worsening, especially when associated with T-cell lymphopenia. Early flow cytometry could help clinicians to target patients at high risk of clinical deterioration. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01995448; URL: www.clinicaltrials.gov.


Subject(s)
Clinical Deterioration , Flow Cytometry/standards , Sepsis/blood , Aged , Female , Humans , Male , Organ Dysfunction Scores , Predictive Value of Tests , Prognosis , Prospective Studies , Survival Analysis
4.
Hematol Oncol ; 36(2): 422-428, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29218734

ABSTRACT

The assessment of minimal residual disease (MRD) in acute myeloblastic leukemia is of growing interest as a prognostic marker of patients' outcome. Multiparameter flow cytometry (MFC), tracking leukemia-associated immunophenotypic patterns, has been shown in several studies to be a useful tool to investigate MRD. Here, we report a multicenter prospective study which allowed to define a harmonized analysis strategy, as well as the efficacy of MFC MRD to predict outcome. This study included 276 patients, in 10 different MFC centers, of whom 268 had at least 1 MRD check point. The combination of a CD45, CD34, and CD33 backbone, with the addition of CD117, CD13, CD7, and CD15 in 2 five-color tubes allowed to define each patient's multiparameter immunophenotypic characteristics at diagnosis, according to a Boolean combination of gates. The same individual diagnosis gating strategy was then applied at each MRD time point for each patient. MRD levels were stratified according to log by log thresholds, from 5 × 10-2 (the classical morphological threshold to define remission) down to <5 × 10-5 . MRD was found to be constantly negative (<5 × 10-5 ) for 148 patients. Survival analyses significantly associated MRD negativity with a good prognosis and any positive value with poorer outcome. All P values were <0.0001 both for disease-free and overall survival at the earliest time point (post-induction, MRD1) as well as when considering all time points together. Finally, MRD levels were independent of cytogenetics and allowed in fact to further stratify all cytogenetics risk groups. In summary, this multicenter study demonstrates that a simple combination of immunophenotypic markers successfully allows for the detection of MRD in acute myeloblastic leukemia patients, with a strong correlation to outcome.


Subject(s)
Flow Cytometry/methods , Leukemia, Myeloid, Acute/diagnosis , Neoplasm, Residual/diagnosis , Adolescent , Adult , Aged , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Immunophenotyping , Infant , Male , Middle Aged , Prognosis , Prospective Studies , Young Adult
5.
Ann Biol Clin (Paris) ; 74(5): 617-631, 2016 Oct 01.
Article in English | MEDLINE | ID: mdl-27707677

ABSTRACT

The HematoFlow™ system is used in the hematology laboratory of the University Hospital of Bordeaux since July, 2011. The HematoFlow™ solution is the combination of a sample preparator (FP1000) and a 5 color flow cytometer (FC500) linked by a middleware (Remisol™). This system is used in second line when flags are activated by the hematology instrument and/or if the sample comes from the OncoHematology Department. Improvements in hematology disease diagnosis and follow-up were possible using this system. The laboratory has now entered in an accreditation procedure and needs to check this method in compliance with the COFRAC requirements.


Subject(s)
Flow Cytometry/instrumentation , Flow Cytometry/standards , Hematologic Diseases/blood , Accreditation , Automation, Laboratory/instrumentation , Automation, Laboratory/methods , Automation, Laboratory/standards , Blood Cell Count/instrumentation , Blood Cell Count/methods , Blood Cell Count/standards , Flow Cytometry/methods , France , Healthy Volunteers , Hematologic Diseases/diagnosis , Hematologic Tests/instrumentation , Hematologic Tests/methods , Hematologic Tests/standards , Humans , Multiple Myeloma/blood , Quality Control , Reproducibility of Results , Sensitivity and Specificity
6.
Oncotarget ; 7(1): 845-59, 2016 Jan 05.
Article in English | MEDLINE | ID: mdl-26625317

ABSTRACT

In spite of intensive research to improve treatment of acute myeloid leukemia (AML) more than half of all patients continue to develop a refractory disease. Therefore there is need to improve AML treatment. The overexpression of the BCL-2 family anti-apoptotic members, like BCL-2 or BCL-xL has been largely reported in lymphoid tumors but also in AML and other tumors. To counteract the anti-apoptotic effect of BCL-2, BH3 mimetics have been developed to target cancer cells. An increase in activity of ERK1/2 mitogen activated protein (MAP) kinase has also been reported in AML and might be targeted by MEK1/2 inhibitors. Hence, in the current work, we investigated whether the association of a BH3 mimetic such ABT-263 and the MEK1/2 inhibitor pimasertib (MEKI), was efficient to target AML cells. A synergistic increasing of apoptosis was observed in AML cell lines and in primary cells without affecting normal bone marrow cells. Such cooperation was confirmed on tumor growth in a mouse xenograft model of AML. In addition we demonstrated that MEKI sensitized the cells to apoptosis through its ability to promote a G1 cell cycle arrest. So, this combination of a MAP Kinase pathway inhibitor and a BH3 mimetic could be a promising strategy to improve the treatment of AML.


Subject(s)
Aniline Compounds/pharmacology , Apoptosis/drug effects , Cell Proliferation/drug effects , MAP Kinase Kinase 1/antagonists & inhibitors , MAP Kinase Kinase 2/antagonists & inhibitors , Niacinamide/analogs & derivatives , Sulfonamides/pharmacology , Acute Disease , Aniline Compounds/administration & dosage , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Cell Line, Tumor , Cell Survival/drug effects , Drug Synergism , G1 Phase Cell Cycle Checkpoints/drug effects , HL-60 Cells , Humans , Immunohistochemistry , Leukemia, Myeloid/drug therapy , Leukemia, Myeloid/metabolism , Leukemia, Myeloid/pathology , MAP Kinase Kinase 1/metabolism , MAP Kinase Kinase 2/metabolism , Mice, Inbred NOD , Mice, Knockout , Mice, SCID , Niacinamide/administration & dosage , Niacinamide/pharmacology , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/pharmacology , Sulfonamides/administration & dosage , Tumor Burden/drug effects , U937 Cells , Xenograft Model Antitumor Assays
7.
Cytometry B Clin Cytom ; 88(6): 375-84, 2015.
Article in English | MEDLINE | ID: mdl-25906976

ABSTRACT

The complete blood cell count and white blood cell differential are the first step in the biological diagnosis of hematological diseases. Both are currently performed by automated instruments which control data and produce alerts. If such flags are activated, the automated differential cannot be validated and the operator must activate a visual blood smear review. Microscopic examination is still today the reference method despite its lack of sensitivity and reproducibility. The HematoFlow™ (Beckman Coulter) system is the first flow cytometry commercialized method designed for the routine differential. Using six markers in five colors and an automated gating strategy, it provides differentials proven to be reliable for 17 leukocyte subpopulations detection. Relying first on a retrospective analysis of 6,462 blood samples processed by HematoFlow™, thresholds were determined to detect the presence of immature granulocytes and/or blast cells. All possible gating strategy misclassifications of leukocyte subpopulations were then summarized in a systematic nomenclature leading to the development of an original flag system based on the detection of aberrant localization of cell events in specific new bivariate histograms. Ultimately, more than 50% of the results could be automatically validated using the HematoFlow™ system, without any false negative, thereby dramatically contributing to an important decrease of technicians' workload. Moreover a noticeable help was given for smear review interpretation and new immunological flags led to the confirmation of blood disease after classical immunophenotyping. These results were confirmed in a second prospective study including 15,335 cases, where more than 50% of the results were automatically validated by this new flag system. MFC stands as being more and more essential for analyzing differentials in routine and this new flag system could greatly improve its implementation.


Subject(s)
Flow Cytometry/methods , Hematologic Tests , Leukocytes/cytology , Blood Cell Count/methods , Humans , Immunophenotyping , Reproducibility of Results , Retrospective Studies
8.
Haematologica ; 97(7): 1036-41, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22532522

ABSTRACT

BACKGROUND: Refractory anemia with ring sideroblasts associated with marked thrombocytosis was proposed as a provisional entity in the 2001 World Health Organization classification of myeloid neoplasms and also in the 2008 version, but its existence as a single entity is contested. We wish to define the clinical features of this rare myelodysplastic/myeloproliferative neoplasm and to compare its clinical outcome with that of refractory anemia with ring sideroblasts and essential thrombocythemia. DESIGN AND METHODS: We conducted a collaborative retrospective study across Europe. Our database included 200 patients diagnosed with refractory anemia with ring sideroblasts and marked thrombocytosis. For each of these patients, each patient diagnosed with refractory anemia with ring sideroblasts was matched for age and sex. At the same time, a cohort of 454 patients with essential thrombocythemia was used to compare outcomes of the two diseases. RESULTS: In patients with refractory anemia with ring sideroblasts and marked thrombocytosis, depending on the Janus Kinase 2 V617F mutational status (positive or negative) or platelet threshold (over or below 600 × 10(9)/L), no difference in survival was noted. However, these patients had shorter overall survival and leukemia-free survival with a lower risk of thrombotic complications than did patients with essential thrombocythemia (P<0.001) but better survival (P<0.001) and a higher risk of thrombosis (P=0.039) than patients with refractory anemia with ring sideroblasts. CONCLUSIONS: The clinical course of refractory anemia with ring sideroblasts and marked thrombocytosis is better than that of refractory anemia with ring sideroblasts and worse than that of essential thrombocythemia. The higher risk of thrombotic events in this disorder suggests that anti-platelet therapy might be considered in this subset of patients. From a clinical point of view, it appears to be important to consider refractory anemia with ring sideroblasts and marked thrombocytosis as a distinct entity.


Subject(s)
Anemia, Refractory/pathology , Anemia, Sideroblastic/pathology , Janus Kinase 2/genetics , Thrombocythemia, Essential/pathology , Thrombocytosis/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Anemia, Refractory/complications , Anemia, Refractory/mortality , Anemia, Sideroblastic/complications , Anemia, Sideroblastic/mortality , Blood Platelets/pathology , Europe , Female , Humans , Male , Middle Aged , Mutation , Platelet Count , Retrospective Studies , Risk Factors , Survival Analysis , Thrombocythemia, Essential/complications , Thrombocythemia, Essential/mortality , Thrombocytosis/complications , Thrombocytosis/mortality
SELECTION OF CITATIONS
SEARCH DETAIL
...